Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Supernus Pharmaceuticals' CEO Jack Khattar to Speak at Jefferies London Healthcare Conference on November 20, 2024 Quiver Quantitative, Inc. - Thu Nov 14, 1:52AM CST

Supernus Pharmaceuticals announced CEO Jack Khattar will participate in a fireside chat at the Jefferies London Healthcare Conference.Quiver AI SummarySupernus Pharmaceuticals, Inc. announced that its...

SUPN : 36.22 (+1.12%)
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference GlobeNewswire - Wed Nov 13, 3:30PM CST

SUPN : 36.22 (+1.12%)
Supernus: Q3 Earnings Snapshot AP - Mon Nov 4, 5:33PM CST

Supernus: Q3 Earnings Snapshot

SUPN : 36.22 (+1.12%)
Supernus Announces Third Quarter 2024 Financial Results GlobeNewswire - Mon Nov 4, 3:05PM CST

SUPN : 36.22 (+1.12%)
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 GlobeNewswire - Thu Oct 31, 3:10PM CDT

SUPN : 36.22 (+1.12%)
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results GlobeNewswire - Mon Oct 21, 3:25PM CDT

SUPN : 36.22 (+1.12%)
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder GlobeNewswire - Thu Oct 17, 3:05PM CDT

SUPN : 36.22 (+1.12%)
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder GlobeNewswire - Thu Oct 10, 4:12PM CDT

SUPN : 36.22 (+1.12%)
Supernus: Q2 Earnings Snapshot AP - Tue Aug 6, 4:36PM CDT

Supernus: Q2 Earnings Snapshot

SUPN : 36.22 (+1.12%)
Supernus: Q4 Earnings Snapshot AP - Tue Feb 27, 5:02PM CST

Supernus: Q4 Earnings Snapshot

SUPN : 36.22 (+1.12%)

Barchart Exclusives

3 High-Yielding Dividend Kings to Boost Your Income in 2025 and Beyond Barchart - Fri Nov 22, 6:00PM CST
These three high-quality companies are currently on sale, offering elevated yields that appeal to dividend growth investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot